Boston Scien Cp Stock Price, News & Analysis

Boston Scientific Corporation (NYSE: BSX) will participate in Citi's 2023 Healthcare Services, MedTech, Tools & HCIT Conference on March 1, 2023. The event will feature a 40-minute question-and-answer session with key executives, Dan Brennan, Chief Financial Officer, and Lauren Tengler, Vice President of Investor Relations, at 8:00 a.m. EST. Interested parties can access a live webcast of the session through the Boston Scientific Investor Relations website, with a replay available one hour post-event. Boston Scientific is dedicated to transforming lives with innovative medical solutions and has been a leader in medical technology for over 40 years.

Boston Scientific emphasizes the importance of career strategies amidst the growing trend of work-life integration. As caregiving responsibilities, particularly among women, have come to the forefront during recent years, the company highlights the need for discussions surrounding career management. According to the CDC, two out of every three caregivers in the U.S. are women, who provide significant support for children and adults with various needs. The press release calls for a renewed focus on how individuals can take charge of their career paths in this evolving landscape.

Boston Scientific Corporation (NYSE: BSX) announced FDA 510(k) clearance for the LithoVue™ Elite Single-Use Digital Flexible Ureteroscope System, the first system to monitor intrarenal pressure in real-time during ureteroscopy. Ureteroscopy is vital for treating kidney stones, affecting about 10% of people. The new system aims to reduce complications from elevated intrarenal pressure, which can lead to severe post-operative issues. Enhancements include improved image quality, updated control features, and streamlined integration with existing operating room systems. Limited market release in the U.S. will begin soon.

Boston Scientific generated net sales of $3.242 billion in Q4 2022, increasing by 3.7% year-over-year. The results reflect an 8.7% operational and 7.1% organic growth, despite a 200 basis point impact from Italian payback provisions. GAAP net income was $126 million or $0.09 EPS, lower than expected guidance. For 2022, total net sales reached $12.682 billion, a 6.7% growth, but GAAP net income fell to $642 million or $0.45 EPS. The company anticipates 5% to 7% net sales growth in 2023 and has announced acquisitions to expand its portfolio.

Boston Scientific Corporation (NYSE: BSX) will attend the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 8:15 a.m. PST in San Francisco, California. CEO Mike Mahoney will present alongside other key executives. Additionally, the company will host a conference call on February 1, 2023, at 8:00 a.m. EST, to discuss its fourth-quarter financial results for the period ending December 31, 2022. A news release will precede this call, providing financial highlights.

Boston Scientific Corporation (BSX) announced a partial offer to acquire up to 65% of Acotec Scientific Holdings Limited for HK$20 per share, totaling approximately US$523 million. Acotec specializes in innovative medical solutions, generating RMB 339 million in sales for the 12 months ending June 30, 2022, reflecting a 25% year-over-year growth. The acquisition aims to enhance Boston Scientific's presence in China and commercialize Acotec's products globally. While the expected impact on adjusted earnings per share is immaterial in 2023, the transaction's completion is subject to shareholder approval.

Boston Scientific has announced a definitive agreement to acquire Apollo Endosurgery for $10 per share, valuing the deal at approximately $615 million. This acquisition aims to enhance Boston Scientific's endoluminal surgery portfolio and expand its presence in the endobariatric market, a growing sector for weight management solutions. Apollo is projected to generate net sales of around $76 million in 2022, driven by its innovative endoscopic suturing systems. The transaction is expected to close in the first half of 2023, with minimal impact on adjusted earnings per share in 2023 but accretive thereafter.

Boston Scientific Corporation (NYSE:BSX) announced the initial results from the ACURATE neo2 Post Market Clinical Follow-up study. Key findings include a high procedural success rate of 98.4%, low mortality rates of 0.8% at 30 days, and minimal paravalvular leaks. The study involved 250 patients and highlighted significant safety and effectiveness of the ACURATE neo2 Aortic Valve System. Notable outcomes included a 6.5% new pacemaker implantation rate and a 0% incidence of disabling stroke. These findings bolster confidence in the valve's design improvements.

Boston Scientific (NYSE: BSX) will participate in two key investor conferences. On November 15, 2022, executives Dan Brennan and Lauren Tengler will engage in a 30-minute Q&A at the 2022 Stifel Healthcare Conference, starting at 8:00 a.m. EST. Following this, on November 30, 2022, Jeff Mirviss, Catherine Jennings, Dr. Michael Jaff, and Lauren Tengler will hold a 45-minute Q&A at the 5th Annual Evercore ISI HealthCONx Conference, also at 8:00 a.m. EST. Live webcasts for both events will be available at investors.bostonscientific.com.